2010 a year of strong delivery

In 2010, over 203 000 patients - almost doubled compared to 2009 - treated with UCB’s new core products in over 27 countries across the globe.

• Total revenue increased by 3% to € 3 218 million driven by the growth of Cimzia®, Vimpat® and Neupro® combined with the solid performance generated by the established product portfolio, including Keppra®
• Strong underlying profitability (recurring EBITDA) of € 731 million; +5%.
• Core earnings per share increased from € 1.74 in 2009 to € 1.99 in 2010.
• Net profit decreased to € 103 million reflecting a strong operational result and higher non-cash, one-time write offs and impairments charges resulting from year end impairment tests partially offset by one-off income taxes. Adjusted net profit increased by 6% to € 239 million.
• Gross dividend of € 0.98 per share (+ 2%) recommended by the UCB Board of Directors
• Pipeline strengthened and moving ahead with seven Phase 3 projects and six Phase 2 projects ongoing in CNS and immunology